
    
      OUTLINE: This is a multi-center study.

      PTK787 daily plus trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease
      evaluation every other cycle.

      Patients may continue treatment until disease progression or toxicity intervenes.

      Performance Status: ECOG 0 or 1

      Life Expectancy: Not specified

      Hematopoietic:

        -  ANC > 1500 mm3

        -  Platelets > 100,000 mm3

        -  Hemoglobin > 9 g/dL

        -  PTT and INR < 1.5 x ULN

      Hepatic:

        -  ALT and AST < 3 x ULN (< 5 x ULN in patients with known liver metastases)

        -  Alkaline phosphatase < 2.5 x ULN

        -  Serum bilirubin < 1.5 x ULN

      Renal:

        -  Serum creatinine < 1.5 x ULN

        -  Proteinuria < 1+ by dipstick OR total urinary protein < 500 mg/24 hours with measured
           creatinine clearance (CrCl) â‰¥ 50 mL/min

      Cardiovascular:

        -  No clinically significant cardiac disease (e.g. congestive heart failure, symptomatic
           coronary artery disease and cardiac arrhythmias not well controlled with medication) or
           myocardial infarction within the last 6 months.

        -  LVEF > LLN by MUGA or ECHO (obtained within 28 days prior to being registered for
           protocol therapy)

      Pulmonary:

        -  Not specified
    
  